Centrophenoxine: Neuroprotective Nootropic for Brain Aging & Cognitive Clarity
60-Second Summary
Centrophenoxine (also known as meclofenoxate) is a synthetic compound studied as a neuroprotective nootropic that may support cognitive function and brain aging. It is theorized to work by enhancing cellular energy metabolism and reducing lipofuscin accumulation—a form of cellular debris linked to neurodegeneration. While primarily investigated in European research and used in some clinical settings, human evidence in healthy populations remains limited, and it is not FDA-approved in the United States. Users considering centrophenoxine should consult a healthcare provider about efficacy and appropriateness.
What is Centrophenoxine?
Centrophenoxine is a synthetic compound developed in France in the 1950s as a nootropic agent—a substance designed to enhance cognitive function and neuroprotection. It is a precursor to DMAE (dimethylaminoethanol) and is sometimes considered an enhanced, more bioavailable form of DMAE with an additional protective moiety (parachlorophenoxyacetate). When ingested, centrophenoxine is metabolized into DMAE and other metabolites that may cross the blood–brain barrier.
The primary mechanism of interest involves enhancement of mitochondrial ATP production and reduction of lipofuscin—an age-related accumulation of oxidized proteins and lipids in neuronal lysosomes. Lipofuscin is associated with cellular senescence and is hypothesized to interfere with normal brain function. Centrophenoxine is also studied for its potential to enhance acetylcholine synthesis and improve cerebral blood flow, though the relative importance of these pathways in humans remains unclear.
Centrophenoxine has been most extensively researched in Europe and some Asian countries, particularly in studies of age-related cognitive decline and dementia. It has not undergone extensive clinical evaluation in the United States and is not FDA-approved as a medication or dietary supplement ingredient there.
Evidence-based benefits of Centrophenoxine
Centrophenoxine is studied primarily for neuroprotection and cognitive support in aging populations. The following benefits have been investigated, though robust evidence in healthy individuals is limited:
Age-Related Cognitive Decline
Preliminary research and some small clinical trials suggest centrophenoxine may help preserve cognitive function in older adults. A proposed mechanism involves reducing lipofuscin accumulation in neurons and improving mitochondrial energy metabolism. However, most studies are decades old, conducted in European populations, and lack the design rigor of modern randomized controlled trials. Evidence is not strong enough to claim proven benefit in healthy aging.
Neuroprotection & Antioxidant Activity
In vitro and animal studies indicate centrophenoxine has antioxidant and membrane-protective properties. It may stabilize neuronal cell membranes and reduce oxidative stress markers in laboratory conditions. Human evidence for these effects is preliminary, and it is unclear whether antioxidant activity in the brain translates to meaningful clinical benefit.
Cerebral Blood Flow & Metabolic Enhancement
Some older European literature reports improvements in cerebral circulation and brain oxygenation following centrophenoxine use. These effects are proposed to occur through enhanced mitochondrial ATP production and improved vascular tone. However, modern imaging studies in healthy human subjects are sparse, and the magnitude of any improvement remains uncertain.
Memory & Verbal Fluency
Anecdotal reports and a few small trials suggest potential modest improvements in memory recall and verbal fluency in older patients with age-related cognitive complaints. No large randomized controlled trials in healthy younger populations have confirmed benefit. Current evidence is observational or preliminary and cannot be generalized widely.
Support in Neurodegenerative Conditions
Centrophenoxine has been investigated as an adjunctive therapy in dementia and age-related neurodegeneration, particularly in European clinical settings. Evidence is preliminary, and centrophenoxine is not approved as a treatment for Alzheimer's disease or other neurodegenerative conditions in most countries. Anyone concerned about cognitive decline should seek comprehensive medical evaluation and evidence-based therapies.
Supplement forms of Centrophenoxine, compared
Centrophenoxine is available in a single primary form as an oral supplement, typically supplied as tablets or capsules containing centrophenoxine HCl (the hydrochloride salt). Some formulations may include centrophenoxine as a component of combination nootropic blends. No major bioavailability variants (e.g. different salt forms with meaningfully different absorption) are commercially prominent in modern supplementation.
How much Centrophenoxine should you take?
Centrophenoxine dose ranges in research and traditional use are typically 250–2000 mg daily, though optimal dosing in humans has never been formally established through large randomized trials. Most historical studies used doses of 500–1000 mg daily, often divided into two or three doses. No RDA or official upper limit exists, and dosing recommendations vary widely across manufacturers and regional clinical practice.
- Typical supplemental range: 500–1000 mg daily, split into two or three doses (e.g., 250 mg three times daily).
- Research-based range: Many older European studies used 500–1000 mg daily; some used up to 2000 mg daily in clinical settings.
- Onset of effect: No robust data exist; some anecdotal reports suggest weeks to months of regular use before perceived cognitive benefit.
- Special populations: No specific dose adjustments are validated for age, kidney, or liver function; consult a healthcare provider if you have renal or hepatic impairment.
Centrophenoxine is typically taken orally with or without food, though some users report better tolerance with meals. Doses are often divided to improve absorption and tolerability. Do not exceed manufacturer recommendations without medical guidance. Combining centrophenoxine with other stimulants, DMAE, or cholinergic supplements may increase the risk of overstimulation; consult a healthcare provider before stacking.
Safety, side effects, and risks
Centrophenoxine has a historical safety record from decades of use in European clinical practice, but rigorous modern safety data in large diverse populations are limited. It is not FDA-regulated as a medication or supplement in the United States, and its long-term safety profile in healthy individuals has not been thoroughly documented in contemporary research.
Common Side Effects
Mild gastrointestinal discomfort, nausea, and appetite suppression have been reported in some users. Nervousness, insomnia, or mild agitation may occur, particularly at higher doses or in sensitive individuals, owing to potential cholinergic and stimulant-like activity. Headache has been reported occasionally. These effects are typically transient and dose-dependent.
Serious Adverse Effects (Rare)
No major serious adverse events have been widely documented in the historical clinical literature, but the absence of evidence does not mean absence of risk, particularly with long-term use. Cholinergic excess (from DMAE and acetylcholine-enhancing effects) could theoretically lead to muscle weakness or bradycardia in susceptible individuals, though such cases are not well-documented. Anyone experiencing chest pain, severe palpitations, or persistent tremor should seek immediate medical attention.
Pregnancy & Lactation
Centrophenoxine has not been adequately studied in pregnant or breastfeeding women. It should be avoided during pregnancy and lactation unless explicitly recommended by an obstetrician, given limited safety data and theoretical risks to fetal development.
Drug Interactions & Medical Conditions
If you have a history of hypertension, heart arrhythmias, anxiety disorders, or sleep disturbances, discuss centrophenoxine use with your healthcare provider, as cholinergic and stimulant effects may be counterproductive. Individuals on acetylcholinesterase inhibitors (used for Alzheimer's disease) should consult a doctor before adding centrophenoxine, owing to risk of additive cholinergic effects. Always inform your healthcare provider of any supplement use, particularly if you take psychoactive medications or have neurological conditions.
Drug and nutrient interactions
- Acetylcholinesterase inhibitors (donepezil, rivastigmine): Centrophenoxine may potentiate cholinergic effects, increasing risk of muscle weakness, bradycardia, or gastrointestinal symptoms. Concurrent use should be monitored by a healthcare provider.
- DMAE supplements: Centrophenoxine is metabolized partly to DMAE; combining with additional DMAE may cause redundant or excessive cholinergic stimulation and increase side-effect risk.
- Cholinergic drugs (bethanechol, carbachol): Additive effects on acetylcholine signaling could heighten cholinergic symptoms; medical supervision is recommended.
- Stimulants (caffeine, amphetamine, methylphenidate): Centrophenoxine may have mild stimulant-like properties; combining with strong stimulants could increase nervousness, insomnia, or cardiovascular stress.
- Anticholinergic medications (benztropine, diphenhydramine): May antagonize centrophenoxine's putative cognitive benefits and increase side-effect risk through opposing mechanisms.
- GABA enhancers (benzodiazepines, GABA supplements): Centrophenoxine may have indirect opposing effects; combining could result in conflicting neural signals; consult a provider.
This list is not exhaustive. Check our interaction checker tool and always consult a healthcare provider before adding centrophenoxine to an existing medication regimen.
Who might benefit — and who shouldn't self-supplement without guidance
| Most Likely to Benefit from Supplementing | Use with Caution or Seek Medical Guidance First |
|---|---|
| Older adults with age-related cognitive complaints seeking neuroprotection (based on historical European clinical practice) | Individuals with uncontrolled hypertension or cardiac arrhythmias, owing to potential cholinergic or stimulant effects |
| Healthy individuals interested in cognitive optimization and longevity support (limited evidence in this population) | Pregnant or breastfeeding women (insufficient safety data) |
| Users already taking DMAE and seeking a more complete neuroprotective profile | Patients on acetylcholinesterase inhibitors or other cholinergic medications without medical clearance |
| Persons interested in reducing cellular aging markers and lipofuscin accumulation (theoretical basis) | Those with active anxiety, insomnia, or mood disorders without medical evaluation, as stimulant-like effects may be counterproductive |
| Individuals in regions where centrophenoxine has established clinical use (e.g., Europe, some Asian countries) | People with kidney or liver disease, owing to unknown safety and clearance profiles in impaired elimination |
Frequently asked questions
Is centrophenoxine safe to take long-term?
Centrophenoxine has a historical safety record from decades of use in European clinical practice, but rigorous modern long-term safety studies in large populations are limited. It is not FDA-approved in the United States, and potential long-term risks—particularly with chronic cholinergic stimulation—have not been thoroughly characterized. Consult a healthcare provider before using centrophenoxine long-term, and undergo periodic medical review if you choose to continue.
What is the difference between centrophenoxine and DMAE?
Centrophenoxine is a synthetic compound that is partly metabolized into DMAE (dimethylaminoethanol) along with other metabolites. It is theorized to be a more complete and stable neuroprotective agent than DMAE alone, owing to the additional protective chemical moiety. However, direct comparative studies in humans are sparse, and both compounds lack robust modern clinical evidence of efficacy.
How long does it take to feel cognitive benefits from centrophenoxine?
There is no clear evidence on onset of effect. Anecdotal reports vary widely, with some users reporting improvements over weeks to months of regular use, while others report no obvious change. Any perceived cognitive benefits should be evaluated cautiously, as placebo effects are common with nootropic supplementation and individual response is highly variable.
Can I stack centrophenoxine with other nootropics?
Combining centrophenoxine with other nootropics—particularly those that enhance cholinergic function (e.g., alpha-GPC, CDP-choline), other stimulants (caffeine, DMAE), or acetylcholinesterase inhibitors—carries a risk of additive or excessive effects. Consult a healthcare provider before combining supplements, especially if you are on any medications or have underlying health conditions.
Does centrophenoxine help with dementia or Alzheimer's disease?
Centrophenoxine has been investigated as a potential adjunctive therapy in dementia and age-related neurodegeneration, but it is not approved as a treatment for Alzheimer's disease or other neurodegenerative conditions in most countries. Anyone concerned about cognitive decline or at risk for dementia should seek comprehensive medical evaluation and evidence-based therapies rather than relying on unproven supplements.
What are the main side effects of centrophenoxine?
Common reported side effects include mild nausea, gastrointestinal discomfort, nervousness, insomnia, and occasional headache. These are typically mild and dose-dependent. More serious effects such as muscle weakness or arrhythmias are rare but theoretically possible owing to cholinergic activity. Stop use and seek medical attention if you experience chest pain, severe palpitations, or persistent tremor.
Is centrophenoxine available as a prescription medication in the US?
No, centrophenoxine is not FDA-approved as a medication in the United States and is not available by prescription. It may be available as a dietary supplement or nootropic from online retailers, but regulatory oversight is minimal. Quality, purity, and safety standards are not guaranteed. Always purchase from reputable sources and consult your healthcare provider before use.
Related ingredients
Alpha Gpc
Related ingredient — see the Alpha Gpc reference page.
Acetyl L Carnitine Alcar
Related ingredient — see the Acetyl L Carnitine Alcar reference page.
Coq10 Coenzyme Q10
Related ingredient — see the Coq10 Coenzyme Q10 reference page.
Bacopa Monnieri
Related ingredient — see the Bacopa Monnieri reference page.
Citicoline
Related ingredient — see the Citicoline reference page.
Alpha Lipoic Acid Ala
Related ingredient — see the Alpha Lipoic Acid Ala reference page.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.